Mubritinib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameMubritinib
Drug Alias Name莫立替尼mubritinibumTAK-165
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsKidney NeoplasmsLung NeoplasmsOvarian Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTakeda Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsKidney NeoplasmsLung NeoplasmsOvarian Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksWikipedia